![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 05, 2018 2:58:22 PM
One could look at success in the PISCES trial as an indicator of what's possible in other solid tumor cancers as well. This may also impact the company's valuation. There is such an enormous unmet need for advanced solid cancers. In the US, for example, I believe there are approximately 40k-50k new cases of TNBC diagnosed each year and only around 5% respond to anti-pd-1 therapy. Would Oncosec's current TNBC trial be factored in to the company's valuation given hypothetical success in the PISCES P2b trial? We already have a glimpse of what happens when anti-pd-1 treatments follow a single treatment cycle of ImmunoPulse IL-12 in TNBC - responses in both patients who went straight to anti-pd-1 treatment. There is mounting evidence now that the ImmunoPulse platform works across multiple solid cancers.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM